There are currently 86 active clinical trials seeking participants for Myelodysplastic Syndromes research studies. The states with the highest number of trials for Myelodysplastic Syndromes participants are Ohio, California, New York and Texas.
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
NCT04419649
Recruiting
The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: City of Hope National Medical Center, Duarte, California +42 locations
Conditions: Myelodysplastic Syndromes, Cytopenia
Register for Updates
Registry of Older Patients With Cancer
NCT01137825
Recruiting
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/24/2024
Locations: Seby B. Jones Cancer Center, Boone, North Carolina +6 locations
Conditions: Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
NCT01890486
Recruiting
To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/10/2024
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases
Register for Updates
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
NCT05457010
Recruiting
The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: City of Hope, Duarte, California +4 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT04904588
Recruiting
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
05/22/2024
Locations: City of Hope National Medical Center, Duarte, California +39 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Register for Updates
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
NCT03310918
Recruiting
This research study is evaluating the impact a collaborative palliative care and oncology team will have on end-of-life outcomes, quality of end-of-life care, and the quality of life, symptoms, and mood of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: ONCOLOGY SPECIALTIES, PC - Clearview Cancer Institute, Huntsville, Alabama +239 locations
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
NCT04902833
Recruiting
This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia
Register for Updates
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774
Recruiting
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Gender:
ALL
Ages:
All
Trial Updated:
03/12/2024
Locations: Massive Bio, Inc, New York, New York
Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Register for Updates
MBG453 in Lower Risk MDS
NCT04823624
Recruiting
This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
Inqovi Maintenance Therapy in Myeloid Neoplasms
NCT04980404
Recruiting
This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant. * This research study involves the study drug Inqovi, which is a combination of the drugs decitabine and cedazuridine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia
Register for Updates
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
NCT05088356
Recruiting
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study, we aim to use RIC followed by matched related/unrelated donor, 7/8 matched related/unrelated donor, or haploidentical donor peripheral blood stem cell transplantation. Standard strategies to control the alloreactivity following HCT util... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: Stanford University, Stanford, California
Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Register for Updates